Penny wise and pound foolish in my estimation. Autologous cancer vaccines are neither like a polio/measles vaccine, nor are they like the flu vaccine. It has theoretical components of both, wrapped up in a very personal mutation chamber -- their own individual immune system.
If companies are waiting for completely enriched off the shelf peptide vaccines covering all mutations, in order that they might conquer all cancer, they should really pursue NWBO, because that is where the pool of information for enrichment is being developed. Additionally, cancer might still escape without an autologous vaccine's broad net. It will do that for quite some time to many cancers.
News 
Market Data 
Discover 
AI
